Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nexsen Limited ( (AU:NXN) ) has issued an update.
Nexsen Limited is an Australian diagnostics company developing rapid point-of-care tests that deliver lab-grade results for conditions traditionally dependent on slower laboratory testing. Its lead product, the GBS Rapid Sensor, targets Group B Streptococcus in maternal health, while additional assays in development address acute kidney injury, chronic kidney disease, and future applications across human health, ag-tech, and biosecurity, positioning the firm to tap large underserved global markets.
By focusing on areas of significant unmet clinical need and building a broad pipeline, Nexsen aims to become a global leader in rapid diagnostics and ensure its tests reach a wide patient population over time.
The company’s half-year report to 31 December 2025 shows a sharp increase in net loss to $4.18 million, reflecting heavier investment in clinical validation, regulatory readiness, and expansion of its diagnostics pipeline. Nexsen prioritised the clinical trial of its GBS Rapid Sensor with Northern Health, advanced quality management systems and regulatory planning for multiple jurisdictions, and refined internal workflows to more quickly adapt its platform to new biomarkers, while maintaining what it describes as a capital-efficient operating model and strengthening governance as a newly listed entity.
No dividends were declared, but net tangible assets per share improved to 3.04 cents from negative 1.61 cents, signalling a stronger balance sheet even as near-term profitability remains under pressure.
More about Nexsen Limited
Nexsen Limited is an Australian diagnostics company developing rapid point-of-care tests that deliver lab-grade results for conditions traditionally dependent on slower laboratory testing. Its lead product, the GBS Rapid Sensor, targets Group B Streptococcus in maternal health, while additional assays in development address acute kidney injury, chronic kidney disease, and future applications across human health, ag-tech, and biosecurity, positioning the firm to tap large underserved global markets.
By focusing on areas of significant unmet clinical need and building a broad pipeline, Nexsen aims to become a global leader in rapid diagnostics and ensure its tests reach a wide patient population over time.
The company’s half-year report to 31 December 2025 shows a sharp increase in net loss to $4.18 million, reflecting heavier investment in clinical validation, regulatory readiness, and expansion of its diagnostics pipeline. Nexsen prioritised the clinical trial of its GBS Rapid Sensor with Northern Health, advanced quality management systems and regulatory planning for multiple jurisdictions, and refined internal workflows to more quickly adapt its platform to new biomarkers, while maintaining what it describes as a capital-efficient operating model and strengthening governance as a newly listed entity.
No dividends were declared, but net tangible assets per share improved to 3.04 cents from negative 1.61 cents, signalling a stronger balance sheet even as near-term profitability remains under pressure.
Average Trading Volume: 263,089
Technical Sentiment Signal: Strong Sell
See more data about NXN stock on TipRanks’ Stock Analysis page.